Skip to main content

The Canadian dollar was little changed against its U.S. counterpart on Tuesday after the pause of a high profile COVID-19 vaccine trial offset robust Chinese trade data, with the currency holding near an earlier five-week high.

Data showing that Chinese exports and imports climbed in September boosted the price of oil, one of Canada’s major exports.

U.S. crude oil futures rose 1.9 per cent to $40.17 a barrel but global equity markets were pressured by news that Johnson & Johnson has paused its COVID-19 vaccine candidate clinical trials because of an unexplained illness in a study participant.

Story continues below advertisement

The Canadian dollar was trading nearly unchanged at 1.3105 to the greenback, or 76.31 U.S. cents. The currency touched its strongest intraday level since Sept. 8 at 1.3095.

Last week, the Canadian dollar notched its largest gain since early June, helped by a rebound in oil prices and hopes for U.S. stimulus, as well as strong domestic jobs data.

Canadian government bond yields were lower across a flatter curve in sympathy with U.S. Treasuries on Tuesday as Canada’s market reopened following the Thanksgiving Day holiday.

The 10-year fell 3.6 basis points to 0.593 per cent, pulling back from its highest since Sept. 1 at 0.646 per cent earlier in the session.

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies